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Christian Vogelberg1*, Petra Moroni-Zentgraf2, Migle Leonaviciute-Klimantaviciene3, Ralf Sigmund4,
Eckard Hamelmann5, Michael Engel2 and Stanley Szefler6Erratum
Following publication of our article [1] we identified an
error in Fig. 5, where results were inadvertently switched
between morning and evening PEF responses. The cor-
rected Fig. 5 is provided in this erratum. The PEF results
provided in our original article text remain correct.
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Fig. 5 Morning and evening PEF response after 4 weeks of treatment (full analysis set). Adjusted for ‘treatment’, ‘period’, ‘patient’ and ‘baseline’.
*p < 0.05 versus placebo Respimat®. PEF, peak expiratory flow
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